Molecular Pathology of Rare Diseases
MolPath-RD
University of California, San Francisco
San Francisco, Estados UnidosPublications in collaboration with researchers from University of California, San Francisco (5)
2024
-
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 10, pp. 725-734
2023
-
Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial
International Journal of Cardiology, Vol. 391
-
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955
2004
-
Oxidation of methionine residues in the prion protein by hydrogen peroxide
Archives of Biochemistry and Biophysics, Vol. 432, Núm. 2, pp. 188-195
2001
-
Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein
Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, Núm. 13, pp. 7170-7175